ckd-379
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 26, 2022 (NCT05452525)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06652971 | Phase 1 | Nov 5, 2024 | Chong Kun Dang Pharmaceutical |
| NCT06204107 | Phase 1 | Nov 21, 2023 | Chong Kun Dang Pharmaceutical, Seoul National University |
| NCT05928637 | Phase 1 | Jul 10, 2023 | Chong Kun Dang Pharmaceutical |
| NCT05952219 | Phase 1 | Jun 2, 2023 | Chonbuk National University, Chong Kun Dang Pharmaceutical |
| NCT05719155 | Phase 1 | Feb 27, 2023 | Chong Kun Dang Pharmaceutical, Seoul National University |
| NCT05452525 | Phase 1 | Jul 26, 2022 | Chong Kun Dang Pharmaceutical, Seoul National University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | For profit | 6 | 6 | 1 | 2022 |
| Seoul National University | Academic/Hospital | 3 | 0 | 1 | 2022 |
| Chonbuk National University | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1